Journal of Yeungnam Medical Science (original) (raw)

Table 1. Summary of the biologics currently approved for severe asthma in Korea

IgE, immunoglobulin E; SC, subcutaneous; IL, interleukin; AEC, absolute blood eosinophil count; IV, intravenous; FeNO, fractional exhaled nitric oxide; OCS, oral corticosteroids.

Xolair, Genentech/Novartis, South San Francisco, CA, USA; Nucala, GlaxoSmithKline, Research Triangle Park, NC, USA; Cinqair, Teva Repatriation, Frazer, PA, USA; Fasenra, MedImmune, Gaithersburg, MD, USA; Dupixent, Regeneron, Tarrytown, NY, USA/Sanofi, Paris, France.

Table 2. Efficacy of the biologics currently approved for severe asthma in Korea

ICS, inhaled corticosteroid; OCS, oral corticosteroid.

Xolair, Genentech/Novartis, South San Francisco, CA, USA; Nucala, GlaxoSmithKline, Research Triangle Park, NC, USA; Cinqair, Teva Repatriation, Frazer, PA, USA; Fasenra, MedImmune, Gaithersburg, MD, USA; Dupixent, Regeneron, Tarrytown, NY, USA/Sanofi, Paris, France.